Page 14 - Accelerate Diagnostics News Today

/PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the fourth quarter and full year ended December 31, 2021....

The firm ended Q4 with 313 revenue-generating ID/AST instruments in the US, with another 81 instruments under contract but not yet live with customers.

Accelerate Diagnostics (NASDAQ:AXDX – Get Rating) will be issuing its quarterly earnings data after the market closes on Tuesday, March 8th. Analysts expect the company to announce earnings of ($0.30) per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link. AXDX stock opened […]

/PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Wednesday, March 8, 2022, at 4:30...

The firm obtained FDA breakthrough device designation for an NGS approach to identify up to 400 bacterial pathogens used to diagnose sepsis and other bacterial infections.

/PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that the company is scheduled to present virtually at the BTIG MedTech, Digital...

/PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that the company is scheduled to present virtually at the BTIG MedTech, Digital...

The company aims to secure the CE-IVD mark for use of its QuickMIC rapid AST system in sepsis and launch sales in Europe in coming months.

The company said that it contracted 16 Pheno instruments with new US customers during Q4 and ended 2021 with 81 instruments in its US backlog.

The company said that it contracted 16 Pheno instruments with new US customers during Q4 and ended 2021 with 81 instruments in its US backlog.